Now showing items 1613-1632 of 3376

    • The Interacting Head Motif Structure Does Not Explain the X-Ray Diffraction Patterns in Relaxed Vertebrate (Bony Fish) Skeletal Muscle and Insect (Lethocerus) Flight Muscle. 

      Knupp, C; Morris, E; Squire, JM (2019-09-14)
      Unlike electron microscopy, which can achieve very high resolution but to date can only be used to study static structures, time-resolved X-ray diffraction from contracting muscles can, in principle, be used to follow the ...
    • The interaction network of the chaperonin CCT 

      Dekker, C; Stirling, PC; McCormack, EA; Filmore, H; Paul, A; Brost, RL; Costanzo, M; Boone, C; Leroux, MR; Willison, KR (NATURE PUBLISHING GROUP, 2008-07-09)
      The eukaryotic cytosolic chaperonin containing TCP-1 (CCT) has an important function in maintaining cellular homoeostasis by assisting the folding of many proteins, including the cytoskeletal components actin and tubulin. ...
    • Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein 

      Tsuzuki, S; Enver, T (2002-05-01)
      Transcription factor GATA-2 Is Implicated in the survival and growth of multipotential progenitors. Here we report that the promyelocytic leukemia zinc finger (PLZF) protein can Interact with GATA-2 and can modify Its ...
    • Interface dosimetry: measurements and Monte Carlo simulations of low-energy photon beams 

      Das, IJ; Kassaee, A; Verhaegen, F; Moskvin, VP (PERGAMON-ELSEVIER SCIENCE LTD, 2001-06)
      A comparison of measured and simulated dose perturbations at high-Z interfaces with Monte Carlo (MC) codes, EGS4, MCNP4B, and PENELOPE, having varied algorithms is presented. The measured dose perturbations strongly depend ...
    • Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. 

      Zhang, AW; McPherson, A; Milne, K; Kroeger, DR; Hamilton, PT; Miranda, A; Funnell, T; Little, N; de Souza, CPE; Laan, S; LeDoux, S; Cochrane, DR; Lim, JLP; Yang, W; Roth, A; Smith, MA; Ho, J; Tse, K; Zeng, T; Shlafman, I; Mayo, MR; Moore, R; Failmezger, H; Heindl, A; Wang, YK; Bashashati, A; Grewal, DS; Brown, SD; Lai, D; Wan, ANC; Nielsen, CB; Huebner, C; Tessier-Cloutier, B; Anglesio, MS; Bouchard-Côté, A; Yuan, Y; Wasserman, WW; Gilks, CB; Karnezis, AN; Aparicio, S; McAlpine, JN; Huntsman, DG; Holt, RA; Nelson, BH; Shah, SP (2018-06)
      High-grade serous ovarian cancer (HGSC) exhibits extensive malignant clonal diversity with widespread but non-random patterns of disease dissemination. We investigated whether local immune microenvironment factors shape ...
    • Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients 

      Matutes, E; Taylor, GP; Cavenagh, J; Pagliuca, A; Bareford, D; Domingo, A; Hamblin, R; Kelsey, S; Mir, N; Reilly, JT (BLACKWELL SCIENCE LTD, 2001-06)
      Adult T-cell leukaemia lymphoma (ATLL) is an aggressive disease caused by the human T-lymphotropic virus 1 (HTLV-I) with a short survival, Responses to interferon alpha (IFN-alpha) and zidovudine (AZT) have been documented ...
    • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. 

      Wyszynski, A; Hong, C-C; Lam, K; Michailidou, K; Lytle, C; Yao, S; Zhang, Y; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; González-Neira, A; Benitez, J; Neuhausen, SL; Brenner, H; Dieffenbach, AK; Meindl, A; Schmutzler, RK; Brauch, H; GENICA Network; Nevanlinna, H; Khan, S; Matsuo, K; Ito, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; kConFab Investigators; Australian Ovarian Cancer Study Group; Wu, AH; Van Den Berg, D; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Couch, FJ; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Dumont, M; Teo, SH; Wong, TY; Kristensen, V; Zheng, W; Long, J; Winqvist, R; Pylkäs, K; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Figueroa, J; Klevebring, D; Czene, K; Hooning, MJ; van den Ouweland, AMW; Darabi, H; Shu, X-O; Gao, Y-T; Cox, A; Blot, W; Signorello, LB; Shah, M; Kang, D; Choi, J-Y; Hartman, M; Miao, H; Hamann, U; Jakubowska, A; Lubinski, J; Sangrajrang, S; McKay, J; Toland, AE; Yannoukakos, D; Shen, C-Y; Wu, P-E; Swerdlow, A; Orr, N; Simard, J; Pharoah, PDP; Dunning, AM; Chenevix-Trench, G; Hall, P; Bandera, E; Amos, C; Ambrosone, C; Easton, DF; Cole, MD (2016-09)
      Breast cancer is the most diagnosed malignancy and the second leading cause of cancer mortality in females. Previous association studies have identified variants on 2q35 associated with the risk of breast cancer. To identify ...
    • Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. 

      Page, EC; Bancroft, EK; Brook, MN; Assel, M; Hassan Al Battat, M; Thomas, S; Taylor, N; Chamberlain, A; Pope, J; Raghallaigh, HN; Evans, DG; Rothwell, J; Maehle, L; Grindedal, EM; James, P; Mascarenhas, L; McKinley, J; Side, L; Thomas, T; van Asperen, C; Vasen, H; Kiemeney, LA; Ringelberg, J; Jensen, TD; Osther, PJS; Helfand, BT; Genova, E; Oldenburg, RA; Cybulski, C; Wokolorczyk, D; Ong, K-R; Huber, C; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oosterwijk, JC; van Zelst-Stams, W; Cook, J; Rosario, DJ; Domchek, S; Powers, J; Buys, S; O'Toole, K; Ausems, MGEM; Schmutzler, RK; Rhiem, K; Izatt, L; Tripathi, V; Teixeira, MR; Cardoso, M; Foulkes, WD; Aprikian, A; van Randeraad, H; Davidson, R; Longmuir, M; Ruijs, MWG; Helderman van den Enden, ATJM; Adank, M; Williams, R; Andrews, L; Murphy, DG; Halliday, D; Walker, L; Liljegren, A; Carlsson, S; Azzabi, A; Jobson, I; Morton, C; Shackleton, K; Snape, K; Hanson, H; Harris, M; Tischkowitz, M; Taylor, A; Kirk, J; Susman, R; Chen-Shtoyerman, R; Spigelman, A; Pachter, N; Ahmed, M; Ramon Y Cajal, T; Zgajnar, J; Brewer, C; Gadea, N; Brady, AF; van Os, T; Gallagher, D; Johannsson, O; Donaldson, A; Barwell, J; Nicolai, N; Friedman, E; Obeid, E; Greenhalgh, L; Murthy, V; Copakova, L; Saya, S; McGrath, J; Cooke, P; Rønlund, K; Richardson, K; Henderson, A; Teo, SH; Arun, B; Kast, K; Dias, A; Aaronson, NK; Ardern-Jones, A; Bangma, CH; Castro, E; Dearnaley, D; Eccles, DM; Tricker, K; Eyfjord, J; Falconer, A; Foster, C; Gronberg, H; Hamdy, FC; Stefansdottir, V; Khoo, V; Lindeman, GJ; Lubinski, J; Axcrona, K; Mikropoulos, C; Mitra, A; Moynihan, C; Rennert, G; Suri, M; Wilson, P; Dudderidge, T; IMPACT Study Collaborators; Offman, J; Kote-Jarai, Z; Vickers, A; Lilja, H; Eeles, RA (2019-12)
      BACKGROUND:Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 ...
    • Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. 

      Siskos, AP; Jain, P; Römisch-Margl, W; Bennett, M; Achaintre, D; Asad, Y; Marney, L; Richardson, L; Koulman, A; Griffin, JL; Raynaud, F; Scalbert, A; Adamski, J; Prehn, C; Keun, HC (2017-01)
      A critical question facing the field of metabolomics is whether data obtained from different centers can be effectively compared and combined. An important aspect of this is the interlaboratory precision (reproducibility) ...
    • Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: A possible interaction with polymorphisms in the interleukin 1 beta gene 

      Lind, H; Zienolddiny, S; Ryberg, D; Skaug, V; Phillips, DH; Haugen, A (2005)
      Summary Tobacco smoking is the main risk factor for lung cancer. Only 10–15% of smokers develop lung cancer, suggesting that genetic factors are of importance in determining individual susceptibility to the disease. Several ...
    • The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway 

      Andreadi, C; Cheung, L-K; Giblett, S; Patel, B; Jin, H; Mercer, K; Kamata, T; Lee, P; Williams, A; McMahon, M; Marais, R; Pritchard, C (COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2012-09-01)
      (L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions ...
    • Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma 

      Hindorf, C; Emfietzoglou, D; Linden, O; Kostarelos, K; Strand, SE (MARY ANN LIEBERT INC, 2005-04)
      Patients with B-cell lymphoma may have disease manifestations ranging in size from more than a 1000 cm(3) down to the volume of a single cell. If targeted radionuclide therapy is to become a curative treatment, all individual ...
    • International consensus statement on the peri-operative management of anaemia and iron deficiency 

      Muñoz, M; Acheson, AG; Auerbach, M; Besser, M; Habler, O; Kehlet, H; Liumbruno, GM; Lasocki, S; Meybohm, P; Rao Baikady, R; Richards, T; Shander, A; So-Osman, C; Spahn, DR; Klein, AA (Wiley, 2017-02)
    • International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. 

      Lee, AW; Ng, WT; Pan, JJ; Poh, SS; Ahn, YC; AlHussain, H; Corry, J; Grau, C; Grégoire, V; Harrington, KJ; Hu, CS; Kwong, DL; Langendijk, JA; Le, QT; Lee, NY; Lin, JC; Lu, TX; Mendenhall, WM; O'Sullivan, B; Ozyar, E; Peters, LJ; Rosenthal, DI; Soong, YL; Tao, Y; Yom, SS; Wee, JT (2018-01)
      PURPOSE:Target delineation in nasopharyngeal carcinoma (NPC) often proves challenging because of the notoriously narrow therapeutic margin. High doses are needed to achieve optimal levels of tumour control, and dosimetric ...
    • International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 

      Terpos, E; Morgan, G; Dimopoulos, MA; Drake, MT; Lentzsch, S; Raje, N; Sezer, O; García-Sanz, R; Shimizu, K; Turesson, I; Reiman, T; Jurczyszyn, A; Merlini, G; Spencer, A; Leleu, X; Cavo, M; Munshi, N; Rajkumar, SV; Durie, BGM; Roodman, GD (2013-06)
      The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.An interdisciplinary panel of clinical experts on MM and myeloma ...
    • The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status 

      Canter, DJ; Nicholson, S; Watkin, N; Hall, E; Pettaway, C (Elsevier BV, 2019-06)
    • Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients. 

      Chen, X; Legrand, AJ; Cunniffe, S; Hume, S; Poletto, M; Vaz, B; Ramadan, K; Yao, D; Dianov, GL (2018-10)
      BACKGROUND:To deliver efficacious personalised cancer treatment, it is essential to characterise the cellular metabolism as well as the genetic stability of individual tumours. In this study, we describe a new axis between ...
    • Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. 

      Lorente, D; Ravi, P; Mehra, N; Pezaro, C; Omlin, A; Gilman, A; Miranda, M; Rescigno, P; Kolinsky, M; Porta, N; Bianchini, D; Tunariu, N; Perez, R; Mateo, J; Payne, H; Terstappen, L; IJzerman, M; Hall, E; de Bono, J (2018-03)
      BACKGROUND:Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic ...